![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
NFT Gaming Company Inc | NASDAQ:NFTG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.2501 | 0.25 | 0.26 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) | (I. R. S. Employer Identification No.) |
(Address of principal executive offices, including ZIP code) |
( |
(Registrant’s telephone number, including area code) |
Not Applicable |
(Former name or former address, if changed since last report) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of exchange on which registered | ||
The |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
On March 13, 2024, Gaxos.ai Inc. (the “Company”), issued a press release announcing the acquisition of rights to use certain AI-enabled technology in order to facilitate the development of its tech for its Gaxos Health proposed product offering.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit No. | Exhibit | |
99.1 | Press Release dated March 13, 2024. | |
104 | Cover Page Interactive Data File (embedded within the XBRL document) |
-1-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GAXOS.AI INC. | ||
March 13, 2024 | By: | /s/ Vadim Mats |
Name: | Vadim Mats | |
Title: | Chief Executive Officer |
-2-
Exhibit 99.1
Gaxos Acquires Rights to AI-enabled Technology from Top Biohacking App
Roseland, NJ / March 13, 2024 – Gaxos.ai Inc. (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced that it had acquired the rights to use certain AI-enabled technology from a top biohacking app, “Ultiself,” in order to facilitate the development of its tech for Gaxos Health.
The integration of Ultiself’s proprietary technology into Gaxos Health’s proposed product offering will enable enhanced customization and user experience aligning with modern-day consumer’s demands for custom and efficient solutions. This move is expected to accelerate Gaxos Health’s development and help solidify its position in the health and wellness industry.
“By securing the rights to use this tech, we will be able to accelerate the development of our AI-enabled application for the Gaxos Health product offering,” said Vadim Mats, CEO of Gaxos.AI. “This tech is intended to allow us to offer a more customized approach to delivering customers diet, nutrition, and tracking capabilities.
The integration process will commence immediately, with both teams working closely to ensure a smooth transition. Gaxos is committed to leveraging this new technology to provide value to its customers and stakeholders.
About Gaxos.ai Inc.
Gaxos.AI isn’t just developing applications; its aim is to redefine the human-AI relationship. Our offerings are being expanded to include health and wellness, as well as gaming. We’re committed to addressing health, longevity, and entertainment, through AI solutions.
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.
Gaxos.ai Inc. Company Contact
Investor Relations
E:ir@gaxos.ai
T: 1-888-319-2499
Cover |
Mar. 13, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Mar. 13, 2024 |
Entity File Number | 001-41620 |
Entity Registrant Name | GAXOS.AI INC. |
Entity Central Index Key | 0001895618 |
Entity Tax Identification Number | 87-3288897 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 101 Eisenhower Pkwy |
Entity Address, Address Line Two | Suite 300 |
Entity Address, City or Town | Roseland |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07068 |
City Area Code | 973 |
Local Phone Number | 275-7428 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0001 |
Trading Symbol | GXAI |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | true |
1 Year NFT Gaming Chart |
1 Month NFT Gaming Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions